18
Feb

Bayer has posted a fresh set of positive data on its hemophilia therapy BAY94-9027. But with a timeline that doesn’t anticipate a regulatory filing until next year, at least one prominent analyst says that Biogen Idec still commands a lead in their race to the market.

…read more

Source: Bayer cites success in hemophilia study, but may still trail Biogen Idec

    

0 No comments